Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 23
HOS-086340 · Präparat HOS-083284
Cardiac and neurologic events have been reported when ritonavir has been co-administered with
disopyramide, mexiletine or nefazodone. The possibility of medicinal product interaction cannot be
excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) mexiletine (HOS-086341) disopyramide (HOS-085595)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 3e3205bf246a43fa53c05345c6686eb58a05b3cedbf0e4cdacfc0d8bf8f3a036 · Zeichen 59911–60123 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56
HOS-086494 · Präparat HOS-083284
Cardiac and neurologic events have been reported when ritonavir has been co-administered with
disopyramide, mexiletine or nefazodone. The possibility of medicinal product interaction cannot be
excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) mexiletine (HOS-086341) disopyramide (HOS-085595)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 18580741ba3efcb6c5b52e5380711fbd61ddb26f1e4bc92d99e80a7d2aa86658 · Zeichen 62309–62519 im Abschnitt
Wechselwirkungen · Sifrol
SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-086614 · Präparat HOS-083320
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with SIFROL.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-30T12:07:00Z · SHA-256 b4f30a08cef428369f4933c2b378c5c4863a47cff3160855eb93c9a7a44d185f · Passage 8e8090250373964867c33aa46943436e77528be4b79a8f09c2a60fb620560a97 · Zeichen 528–1178 im Abschnitt
Wechselwirkungen · Sifrol
SIFROL 0.26 mg prolonged-release tablets SIFROL 0.52 mg prolonged-release tablets SIFROL 1.05 mg prolonged-release tablets SIFROL 1.57 mg prolonged-release tablets SIFROL 2.1 mg prolonged-release tablets SIFROL 2.62 mg prolonged-release tablets SIFROL 3.15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-086639 · Präparat HOS-083320
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with SIFROL.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-30T12:07:00Z · SHA-256 b4f30a08cef428369f4933c2b378c5c4863a47cff3160855eb93c9a7a44d185f · Passage 8e8090250373964867c33aa46943436e77528be4b79a8f09c2a60fb620560a97 · Zeichen 528–1178 im Abschnitt
Wechselwirkungen · Mirapexin
MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-086658 · Präparat HOS-083333
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with
MIRAPEXIN.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T09:14:00Z · SHA-256 10b100c75ddc71f5dd2ebff9e8c7467440f96455ec4517ce8521647f7acf11e0 · Passage c3d535d02c07dc607a17c04a61ed80b6fe9c1368f787d3518bc7b336caa51a8f · Zeichen 528–1181 im Abschnitt
Wechselwirkungen · Mirapexin
MIRAPEXIN 0.26 mg prolonged-release tablets MIRAPEXIN 0.52 mg prolonged-release tablets MIRAPEXIN 1.05 mg prolonged-release tablets MIRAPEXIN 1.57 mg prolonged-release tablets MIRAPEXIN 2.1 mg prolonged-release tablets MIRAPEXIN 2.62 mg prolonged-release tablets MIRAPEXIN 3.15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-086680 · Präparat HOS-083333
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with
MIRAPEXIN.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T09:14:00Z · SHA-256 10b100c75ddc71f5dd2ebff9e8c7467440f96455ec4517ce8521647f7acf11e0 · Passage c3d535d02c07dc607a17c04a61ed80b6fe9c1368f787d3518bc7b336caa51a8f · Zeichen 528–1181 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 14–15
HOS-116357 · Präparat HOS-094447
14
HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir†
Lopinavir/ritonavir lopinavir AUC ↑ 9% Due to a decrease in the exposure
400/100 mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%,
lopinavir Cmax ↓ 2% appropriate doses of the
darunavir AUC ↓ 38% ‡ combination have not been
darunavir Cmin ↓ 51% ‡ established. Hence, concomitant
‡ use of boosted PREZISTA and the
darunavir Cmax ↓ 21%
Lopinavir/ritonavir combination product
lopinavir AUC ↔
533/133.3 mg twice daily lopinavir/ritonavir is
lopinavir Cmin ↑ 13% contraindicated (see section 4.3).
lopinavir Cmax ↑ 11%
darunavir AUC ↓ 41%
darunavir Cmin ↓ 55%
darunavir Cmax ↓ 21%
‡
based upon non dose normalised values
CCR5 ANTAGONIST
Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be
150 mg twice dailymaraviroc Cmin ND 150 mg twice daily when
maraviroc Cmax ↑ 129% co-administered with boosted
darunavir, ritonavir concentrations were PREZISTA.
consistent with historical data
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical considerations Co-administration of boosted
PREZISTA is expected to increase PREZISTA and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of alfentanil The concomitant use with boosted
is mediated via CYP3A, and may as such PREZISTA may require to lower
be inhibited by boosted PREZISTA. the dose of alfentanil and requires
monitoring for risks of prolonged
or delayed respiratory depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Boosted PREZISTA is Caution is warranted and
Flecainide expected to increase these antiarrhythmic therapeutic concentration
Lidocaine (systemic) plasma concentrations. monitoring, if available, is
Mexiletine (CYP3A and/or CYP2D6 inhibition) recommended for these
Propafenone antiarrhythmics when
co-administered with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) lopinavir (HOS-086269) propafenone (HOS-084530) protease (HOS-085623) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) maraviroc (HOS-086186) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 79aee1bbebf74d1fc7eeb1f64d47f744ae971edc2caad3984bd946f3f467a703 · Zeichen 24118–27577 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56–57
HOS-116516 · Präparat HOS-094447
56
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. PREZISTA is expected to Caution is warranted and
Flecainide increase these antiarrhythmic plasma therapeutic concentration
Lidocaine (systemic) concentrations. monitoring, if available, is
Mexiletine (CYP3A and/or CYP2D6 inhibition) recommended for these
Propafenone antiarrhythmics when
co-administered with PREZISTA
with low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 57e505293229728296e7dd8480ad0507531ed8d1e94d1f9e07e41fe182a75b64 · Zeichen 20406–21075 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 96–97
HOS-116607 · Präparat HOS-094447
96
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Boosted PREZISTA is Caution is warranted and
Flecainide expected to increase these antiarrhythmic therapeutic concentration
Lidocaine (systemic) plasma concentrations. monitoring, if available, is
Mexiletine (CYP3A and/or CYP2D6 inhibition) recommended for these
Propafenone antiarrhythmics when
co-administered with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 5cac255293c32ad7098b72d522874806c8c8aed78e7987304d34a5d7988d62d9 · Zeichen 27130–27790 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-119738 · Präparat HOS-095005
9
Integrase Strand Transfer Inhibitors
Dolutegravir dolutegravir Etravirine significantly
50 mg once daily AUC ↓ 0.29 (0.26-0.34) reduced plasma
Cmin ↓ 0.12 (0.09-0.16) concentrations of
Cmax ↓ 0.48 (0.43-0.54) dolutegravir. The effect of
etravirine etravirine on dolutegravir
AUC ↔a plasma concentrations was
Cmin ↔a mitigated by
Cmax ↔a co-administration of
darunavir/ritonavir or
Dolutegravir + dolutegravir lopinavir/ritonavir, and is
darunavir/ritonavir AUC↓ 0.75 (0.69-0.81) expected to be mitigated by
50 mg once daily + Cmin ↓ 0.63 (0.52-0.77) atazanavir/ritonavir.
600/100 mg twice daily Cmax ↓ 0.88 (0.78-1.00)
etravirine INTELENCE should only be
AUC ↔a used with dolutegravir when
Cmin ↔a co-administered with
Cmax ↔a atazanavir/ritonavir,
darunavir/ritonavir, or
Dolutegravir + dolutegravir lopinavir/ritonavir. This
Lopinavir/ritonavir AUC↔ 1.11(1.02-1.20) combination can be used
50 mg once daily + Cmin ↑ 1.28 (1.13-1.45) without dose adjustment.
400/100 mg twice daily Cmax ↔ 1.07 (1.02-1.13)
etravirine
AUC ↔a
Cmin ↔a
Cmax ↔a
Raltegravir raltegravir INTELENCE and raltegravir
400 mg twice daily AUC ↓ 0.90 (0.68-1.18) can be used without dose
Cmin ↓ 0.66 (0.34-1.26) adjustments.
Cmax ↓ 0.89 (0.68-1.15)
etravirine
AUC ↔ 1.10 (1.03-1.16)
Cmin ↔ 1.17 (1.10-1.26)
Cmax ↔ 1.04 (0.97-1.12)
ANTIARRHYTHMICS
Digoxin digoxin INTELENCE and digoxin
0.5 mg single dose AUC ↑ 1.18 (0.90-1.56) can be used without dose
Cmin ND adjustments. It is
Cmax ↑ 1.19 (0.96-1.49) recommended that digoxin
levels be monitored when
digoxin is combined with
INTELENCE.
Amiodarone Not studied. INTELENCE is expected to Caution is warranted and
Bepridil decrease plasma concentrations of these therapeutic concentration
Disopyramide antiarrhythmics. monitoring, if available, is
Flecainide recommended for
Lidocaine (systemic) antiarrhythmics when
Mexiletine co-administered with
Propafenone INTELENCE.
Quinidine
ANTIBIOTICS
Azithromycin Not studied. Based on the biliary elimination INTELENCE and
pathway of azithromycin, no drug interactions azithromycin can be used
are expected between azithromycin and without dose adjustments.
INTELENCE.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) bepridil (HOS-085612) dolutegravir (HOS-089992) quinidine (HOS-085593) digoxin (HOS-086172) azithromycin (HOS-088112) disopyramide (HOS-085595) darunavir (HOS-086181) raltegravir (HOS-086187) ritonavir (HOS-084521) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 88eab8e7a4aadd0b0d68eee60d8b6c66c61e5724eefbfde8ea7e2649457e571e · Zeichen 11566–16118 im Abschnitt
Wechselwirkungen · Pramipexole Teva
Pramipexole Teva 0.088 mg tablets Pramipexole Teva 0.18 mg tablets Pramipexole Teva 0.35 mg tablets Pramipexole Teva 0.7 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119859 · Präparat HOS-095037
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34 %, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with
Pramipexole Teva.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-02T17:36:00Z · SHA-256 5d166932f43f2c779defb4b949fcb54f71a25cc3c96586af3caa034b7968230d · Passage 9612017193804eaed13008b81d23b6818915877f495ddeb3c0feb065e277c878 · Zeichen 529–1189 im Abschnitt
Wechselwirkungen · Oprymea
Oprymea 0.088 mg tablets Oprymea 0.18 mg tablets Oprymea 0.35 mg tablets Oprymea 0.7 mg tablets Oprymea 1.1 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119883 · Präparat HOS-095045
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine,amantadine mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact with
pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose should
be considered when these medicinal products are administered concomitantly with Oprymea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-21T15:55:00Z · SHA-256 ef6b504b25a946790ad124743fb58ae808e01ef5376201d6754036bc75da52e2 · Passage 2fdce5dc531858bbce43c87a98e2962959fe2618a603b974e30acb20dea40533 · Zeichen 527–1176 im Abschnitt
Wechselwirkungen · Oprymea
Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets Oprymea 1.57 mg prolonged-release tablets Oprymea 2.1 mg prolonged-release tablets Oprymea 2.62 mg prolonged-release tablets Oprymea 3.15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-119906 · Präparat HOS-095045
Inhibitors/competitors of active renal elimination pathway
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with Oprymea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-21T15:55:00Z · SHA-256 ef6b504b25a946790ad124743fb58ae808e01ef5376201d6754036bc75da52e2 · Passage a81b331c51d21971ec198f1baf2e2b7c7f649d675f0c36d1d3422ffb4447ae79 · Zeichen 527–1178 im Abschnitt
Wechselwirkungen · Oprymea
Treatment initiation pack Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 33–34
HOS-119927 · Präparat HOS-095045
33
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by
inhibition of the cationic secretory transport system of the renal tubules. Therefore, medicinal products
that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, such as
cimetidine, amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide, may interact
with pramipexole resulting in reduced clearance of pramipexole. Reduction of the pramipexole dose
should be considered when these medicinal products are administered concomitantly with Oprymea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) cimetidine (HOS-085835) mexiletine (HOS-086341) cisplatin (HOS-086022) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-21T15:55:00Z · SHA-256 ef6b504b25a946790ad124743fb58ae808e01ef5376201d6754036bc75da52e2 · Passage 310b41eb637c07db4e7b10aeb2c74f8b22c2661ab8b99d1af6d9f9f8b5d59d99 · Zeichen 637–1233 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-134000 · Präparat HOS-097520
16
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic areas levels. co-administration with Genvoya
Mean percent change in AUC,
Cmax, Cmin1
ANTIARRHYTHMICS
Digoxin (0.5 mg single dose)/ Digoxin: It is recommended that digoxin
Cobicistat (150 mg multiple doses) AUC: ↔ levels be monitored when digoxin is
Cmax: ↑ 41% combined with Genvoya.
Disopyramide Interaction not studied with any of Caution is warranted and clinical
Flecainide the components of Genvoya. monitoring is recommended upon
Systemic lidocaine co-administration with Genvoya.
Mexiletine Concentrations of these
Propafenone antiarrhythmic drugs may be
increased when co-administered
with cobicistat.
ANTI-HYPERTENSIVES
Metoprolol Interaction not studied with any of Clinical monitoring is recommended
Timolol the components of Genvoya. and a dose decrease may be
necessary when these agents are
Concentrations of beta-blockers co-administered with Genvoya.
may be increased when
co-administered with cobicistat.
Amlodipine Interaction not studied with any of Clinical monitoring of therapeutic
Diltiazem the components of Genvoya. effects and adverse reactions is
Felodipine recommended when these medicinal
Nicardipine Concentrations of calcium channel products are concomitantly
Nifedipine blockers may be increased when administered with Genvoya.
Verapamil co-administered with cobicistat.
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Interaction not studied with any of Alternative endothelin receptor
the components of Genvoya. antagonists may be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nifedipine (HOS-086289) propafenone (HOS-084530) nicardipine (HOS-090619) felodipine (HOS-108908) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) amlodipine (HOS-086287) digoxin (HOS-086172) calcium (HOS-085615) disopyramide (HOS-085595) bosentan (HOS-086291) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage fbc226f308d5b4a973e812dce29188ec92b05700c50154ad831ac93b6af736fa · Zeichen 32099–34742 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-134488 · Präparat HOS-097580
12
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
Alfuzosin Based on theoretical considerations Co-administration of darunavir with
darunavir is expected to increase low dose ritonavir and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of The concomitant use with darunavir
alfentanil is mediated via CYP3A, and and low dose ritonavir may require
may as such be inhibited by darunavir to lower the dose of alfentanil and
co-administered with low dose requires monitoring for risks of
ritonavir. prolonged or delayed respiratory
depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Darunavir is expected to Caution is warranted and
Flecainide increase these antiarrhythmic plasma therapeutic concentration
Lidocaine concentrations. monitoring, if available, is
(systemic) (CYP3A and/or CYP2D6 inhibition) recommended for these
Mexiletine antiarrhythmics when co-
Propafenone administered with darunavir with
low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 9518a303c5be83b8c623da21f0ef8178c9138853ea1049de3dcd627347157795 · Zeichen 19313–21059 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-134613 · Präparat HOS-097580
53
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir†
Lopinavir/ritonavir 400/100 lopinavir AUC ↑ 9% Due to a decrease in the exposure
mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%,
lopinavir Cmax ↓ 2% appropriate doses of the combination
have not been established. Hence,
darunavir AUC ↓ 38%‡ concomitant use of boosted darunavir
darunavir Cmin ↓ 51%‡ and the combination product
darunavir Cmax ↓ 21%‡ lopinavir/ritonavir is contraindicated
Lopinavir/ritonavir lopinavir AUC ↔ (see section 4.3).
533/133.3 mg twice daily lopinavir Cmin ↑ 13%
lopinavir Cmax ↑ 11%
darunavir AUC ↓ 41%
darunavir Cmin ↓ 55%
darunavir Cmax ↓ 21%
‡
based upon non dose normalised
values
CCR5 ANTAGONIST
Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be 150
150 mg twice daily maraviroc Cmin ND mg twice daily when co-administered
maraviroc Cmax ↑ 129% with boosted darunavir.
darunavir, ritonavir concentrations
were consistent with historical data
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical considerations Co-administration of boosted
darunavir is expected to increase darunavir and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of The concomitant use with boosted
alfentanil is mediated via CYP3A, darunavir may require to lower the
and may as such be inhibited by dose of alfentanil and requires
boosted darunavir. monitoring for risks of prolonged or
delayed respiratory depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Boosted darunavir is Caution is warranted and ther apeutic
Flecainide expected to increase these concentration monitoring, if
Lidocaine (systemic) antiarrhythmic plasma available, is recommended for these
Mexiletine concentrations. antiarrhythmics when co-
Propafenone (CYP3A and/or CYP2D6 administered with boosted darunavir.
inhibition)
Amiodarone Bepridil Co-administration of boosted
Dronedarone Ivabradine darunavir and amiodarone, bepridil,
Quinidine Ranolazine dronedarone, ivabradine, quinidine,
or ranolazine is contraindicated (see
section 4.3).
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is recommended
digoxin Cmax ↑ 29% that the lowest possible dose of
(↑ digoxin from probable inhibition digoxin should initially be prescribed
of P-gp) in case digoxin is given to patients on
boosted darunavir therapy. The
digoxin dose should be carefully
titrated to obtain the desired clinical
effect while assessing the overall
clinical state of the subject.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) lopinavir (HOS-086269) propafenone (HOS-084530) dronedarone (HOS-086144) protease (HOS-085623) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) disopyramide (HOS-085595) maraviroc (HOS-086186) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 737ba554b4078e65ecf09cd520335cc5df12785cb4f30673452d55d887588655 · Zeichen 22720–27726 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-138479 · Präparat HOS-098200
9
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Based on theoretical Caution is warranted and
Flecainide considerations DRV/COBI is concentration monitoring, if
Mexiletine expected to increase these available, is recommended for
Propafenone antiarrhythmic plasma these antiarrhythmics when
Lidocaine (systemic) concentrations. co-administered with Symtuza.
(CYP3A inhibition)
Co-administration of
Amiodarone amiodarone, dronedarone,
Dronedarone ivabradine, quinidine, or
Ivabradine ranolazine and Symtuza is
Quinidine contraindicated (see section 4.3).
Ranolazine
Digoxin Based on theoretical It is recommended that the lowest
considerations DRV/COBI is possible dose of digoxin should
expected to increase digoxin initially be given to patients on
plasma concentrations. Symtuza. The digoxin dose
(P-glycoprotein inhibition) should be carefully titrated to
obtain the desired clinical effect
while assessing the overall
clinical state of the subject.
ANTIBIOTIC
Clarithromycin Based on theoretical Caution should be exercised
considerations clarithromycin is when clarithromycin is combined
expected to increase darunavir with Symtuza.
and/or cobicistat plasma
concentrations. For patients with renal
(CYP3A inhibition) impairment the Summary of
Concentrations of clarithromycin Product Characteristics for
may be increased upon clarithromycin should be
co-administration with consulted for the recommended
DRV/COBI. dose.
(CYP3A inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Based on theoretical Co-administration of Symtuza
Rivaroxaban considerations co-administration of with a direct oral anticoagulant
Symtuza with these anticoagulants (DOAC) that is metabolised by
may increase concentrations of the CYP3A4 and transported by P-gp
anticoagulant. is not recommended as this may
(CYP3A and/or P-glycoprotein lead to an increased bleeding
inhibition) risk.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) dronedarone (HOS-086144) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) quinidine (HOS-085593) digoxin (HOS-086172) rivaroxaban (HOS-086236) lead (HOS-085592) disopyramide (HOS-085595) clarithromycin (HOS-084517) apixaban (HOS-112091) ivabradine (HOS-109426) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 16be5409503bc03e649799dffc8cd2afca527a103a3ef9517c3e4820acf237b6 · Zeichen 7326–10593 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.